The company has completed the pre approval inspection (PAI) for an active pharmaceutical ingredient (API) manufactured at its Units 1&3, located at Visakhapatnam by the United States Food and Drug Administration, Laurus Labs said in a filing to the BSE. The inspection was completed with three observations, 'which are procedural in nature'.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2KKzOI2
via IFTTT
0 comments:
Post a Comment